Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Ligand Second Quarter 2020 Earnings Webcast

More Info »
Portfolio
Technologies
Licensing Opportunities

Latest News

Ligand to Acquire Pfenex Inc.

Read More

CStone Announces That OmniAb-derived CS1001 (Anti-PD-L1) Phase 3 Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Announces Plans to Submit a New Drug Application

Read More

Ligand Reports Second Quarter 2020 Financial Results

Read More

Recent Events

Stock Snapshot

LGND
Nasdaq
Volume
Market Cap
Day Range
52-Week Range